Show simple item record

Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day −1 ) in the treatment of cutaneous or lymphocutaneous sporotrichosis

dc.contributor.authorChapman, S. W.en_US
dc.contributor.authorPappas, Peter G.en_US
dc.contributor.authorKauffmann, C.en_US
dc.contributor.authorSmith, E. B.en_US
dc.contributor.authorDietze, R.en_US
dc.contributor.authorTiraboschi-Foss, N.en_US
dc.contributor.authorRestrepo, A.en_US
dc.contributor.authorBustamante, A. B.en_US
dc.contributor.authorOpper, C.en_US
dc.contributor.authorEmady-Azar, S.en_US
dc.contributor.authorBakshi, R.en_US
dc.date.accessioned2010-06-01T20:58:51Z
dc.date.available2010-06-01T20:58:51Z
dc.date.issued2004-02en_US
dc.identifier.citationChapman, S. W.; Pappas, P.; Kauffmann, C.; Smith, E. B.; Dietze, R.; Tiraboschi-Foss, N.; Restrepo, A.; Bustamante, A. B.; Opper, C.; Emady-Azar, S.; Bakshi, R. (2004). "Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day −1 ) in the treatment of cutaneous or lymphocutaneous sporotrichosis." Mycoses 47(1-2): 62-68. <http://hdl.handle.net/2027.42/74074>en_US
dc.identifier.issn0933-7407en_US
dc.identifier.issn1439-0507en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74074
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14998402&dopt=citationen_US
dc.format.extent107924 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Verlag, GmbHen_US
dc.rights2004 Blackwell Publishing Ltden_US
dc.subject.otherSporotrichosisen_US
dc.subject.otherLymphocutaneous Infectionen_US
dc.subject.otherAntimycotic Chemotherapyen_US
dc.subject.otherTerbinafineen_US
dc.subject.otherEfficacyen_US
dc.subject.otherSporotrichoseen_US
dc.subject.otherLymphokutane Infektionen_US
dc.subject.otherAntimykotische Chemotherapieen_US
dc.subject.otherTerbinafinen_US
dc.subject.otherWirksamkeiten_US
dc.titleComparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day −1 ) in the treatment of cutaneous or lymphocutaneous sporotrichosisen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDentistryen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical School and Veteran Affairs Medical Centre, Ann Arbour, MI, USAen_US
dc.contributor.affiliationotherUniversity of Mississippi Medical Center, Jackson, MS, USAen_US
dc.contributor.affiliationotherUniversity of Alabama, Birmingham, AL, USAen_US
dc.contributor.affiliationotherUniversity of New Mexico, Albuquerque, NM, USAen_US
dc.contributor.affiliationotherNÚcleo de DoenÇas Infecciosas, Universidade Ferderal do Espirito Santo, Vitoria, Brazilen_US
dc.contributor.affiliationotherUniversity of SÃo Paulo, RibeirÃo Preto, SÃo Paulo, Brazilen_US
dc.contributor.affiliationotherNational University of Columbia, Medellin, Columbiaen_US
dc.contributor.affiliationotherInstituto de Medicina Tropical ‘Alexander von Humboldt’, Universidad Peruana Cayetano Heredia, Lima, Peruen_US
dc.contributor.affiliationotherNovartis Pharmaceuticals Corporation, East Hanover, NJ, USAen_US
dc.contributor.affiliationotherNovartis Pharma AG, Basel, Switzerlanden_US
dc.identifier.pmid14998402en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74074/1/j.1439-0507.2003.00953.x.pdf
dc.identifier.doi10.1046/j.1439-0507.2003.00953.xen_US
dc.identifier.sourceMycosesen_US
dc.identifier.citedreferenceKwon-Chung KJ, Bennet JE. Sporotrichosis. In: Kwon-Chung KJ, Bennett JE ( eds ), Medical Mycology. Philadelphia: Lea & Febiger, 1992: 707 – 29.en_US
dc.identifier.citedreferenceHajjeh R, McDonnell S, Reef S et al. Outbreaks of sporotrichosis among tree nursery workers. J Infect Dis 1997; 176: 499 – 504.en_US
dc.identifier.citedreferenceChapman SW, Daniel CR. Cutaneous manifestations of fungal infection. Infect Dis Clin N Am 1994; 95: 879 – 910.en_US
dc.identifier.citedreferenceWinn RE. Sporotrichosis. Infect Dis Clin N Am 1988; 2: 899 – 911.en_US
dc.identifier.citedreferenceRex JH, Bennet JE. Administration of potassium iodide to normal volunteers does not increase killing of Sporothrix schenckii by their neutrophils or monocytes. J Med Vet Mycol 1990; 28: 185 – 9.en_US
dc.identifier.citedreferenceKauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21: 981 – 5.en_US
dc.identifier.citedreferenceKauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 684 – 7.en_US
dc.identifier.citedreferenceEvans EGV, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in the treatment of toenail onychomycosis. BMJ 1999; 318: 1031 – 5.en_US
dc.identifier.citedreferenceSigurgeirsson B, Olafsson JH, Steinsson JB et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353 – 7.en_US
dc.identifier.citedreferenceRyder NS, Leitner I. In vitro activity of terbinafine (Lamisil): an update. J Dermatol Treat 1998; 9: S23 – 8.en_US
dc.identifier.citedreferenceShadomy S, Espinel-Ingroff A, Gebhart RJ. In-vitro studies with SF 86–327, a new orally active allylamine derivative. Sabouradia 1985; 23: 125 – 32.en_US
dc.identifier.citedreferenceHull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 1992; 126 ( Suppl. 39 ): 51 – 55.en_US
dc.identifier.citedreferenceForsana CV, Carrozzo V, Forte I, Peserico A. Cutaneous lymphangitic sporotrichosis treated with terbinafine. Acta Dermatol Venereol 1994; 3: 161 – 3.en_US
dc.identifier.citedreferenceKudoh K, Kamei E, Terunama A et al. Successful treatment of cutaneous sporotrichosis with terbinafine. J Dermatol Treat 1996; 7: 33 – 35.en_US
dc.identifier.citedreferenceJacyk WK, Ayerst KF, RÖscher M. Sporotrichosis. Review of sixty-five cases from South Africa. Mikol Lek 2000; 7: 189 – 96.en_US
dc.identifier.citedreferenceMorishita N, Yamazaki K, Ninomiya J et al. A case of lymphocutaneous sporotrichosis. Nippon Ishinkin Gakkai Zasshi 2001; 42: 149 – 54.en_US
dc.identifier.citedreferenceMorris-Jones R, Sarkany R, Hay J. Lymphocutaneous sporotrichosis. Br J Dermatol 2001; 145: 38 – 39.en_US
dc.identifier.citedreferencePetranyi G, Meingassner JG, Mieth H. Antifungal activity of allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987; 31: 1365 – 8.en_US
dc.identifier.citedreferenceHay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol 1999; 141: 36 – 40.en_US
dc.identifier.citedreferencePerez A. Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases. Mycoses 1999; 42 ( Suppl. 2 ): 111 – 4.en_US
dc.identifier.citedreferenceLesher JL, Fitch MH, Dunlap DB. Subclinical hypothyroidism during potassium iodide therapy for lymphocutaneous sporotrichosis. Cutis 1994; 53: 128 – 30.en_US
dc.identifier.citedreferenceScully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital: case 28, 1994. N Engl J Med 1994; 331: 181 – 7.en_US
dc.identifier.citedreferenceConti Diaz IA, Civilia E, Gezule E et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35: 153 – 6.en_US
dc.identifier.citedreferenceSharkey-Mathis PK, Kauffman CA, Graybill JR et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993; 95: 279 – 85.en_US
dc.identifier.citedreferenceKarakayali G, Lenk N, Ali N, Gungor E, Artuz F. Itraconazole therapy for lymphocutaneous sporotrichosis: a case report and review of the literature. Cutis 1998; 61: 106 – 7.en_US
dc.identifier.citedreferenceFaergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121 – 6.en_US
dc.identifier.citedreferenceAdel-Rhaman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann Pharmacother 1997; 31: 445 – 56.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.